Latest Breaking News On - Oncology communications - Page 1 : comparemela.com

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalNew jerseySan antonioEast hanoverComunidad autonoma de catalunaIsabella zinckJeff legosNicole zinsli sommFloriana riccio furnariSamir shahParag mahantiJulie masowSloan simpsonDenisea yardleyAlina levchuk

Novartis provides update on Phase III CANOPY-A study

Phase III CANOPY-A trial did not meet primary endpoint of disease-free survival in patients with stages II-IIIA and IIIB completely resected non-small.

United statesIsabella zinckJeff legosVeronique boissonnasNicole zinsli sommBiochim biophys actaSamir shahJulie masowParag mahantiSloan simpsonAlina levchukGlobal oncology communicationsAmerican joint committee on cancerWorld health organizationNovartis us external communicationsNovartis external communications

Lambert Information Database - O Dwyer PR

Premier database and directory of PR firms & public relations agencies. Find the firm that best suits your needs.

New yorkUnited statesHillsdale collegeCentral michigan universityDrexel burnham lambertSarah smithMegan lambertMarilyn hornPaige wirthRania azabMichelle olsonTrudy kremerPeter finnWalter wardWalker sandsPaige wirth lambert

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing.

United statesJulie masowSloan simpsonActa neuropatholDan connellyPrnewswire novartisAnticancer fundAmerican society of clinical oncologyNovartis oncology communicationsNovartis external communicationsExchange commissionNj novartis pharmaceuticals corporationNovartis pharmaceuticals corpSafety informationPrescribing informationEast hanover

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer

United statesJuergen wolfIsabella zinckLe mouhaerVeronique boissonnasNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonAlina levchukGlobal oncology communicationsAmerican society of clinical oncologyEuropean commissionWorld health organizationUniversity hospital cologne